The association of PD-L2 expression with clinical outcomes has also been found to vary between tumor types; in head and neck squamous cell carcinoma tumor specimens, high expression of PD-L2 was associated with shorter OS (39), whereas high expression of PD-L2 (at either 5% and 20% cutoffs) was found to prolong survival in patients with melanoma (40). The gene discussed is PDCD1LG2; the disease is melanoma.